Testosterone Replacement Therapy and Prostate Health: What the Research Says

Older Concerns, Newer Evidence

For years, doctors have approached testosterone replacement therapy (TRT) with caution when treating men who have or are at risk of prostate complications. The fear: that boosting testosterone could fuel prostate growth or cancer. But a fresh review of the evidence, published by EMJ, is challenging that long-held assumption.

The review looked at multiple studies involving men with benign prostatic hyperplasia (BPH) and even those with a history of prostate cancer. The findings suggest that, in many cases, TRT does not significantly worsen prostate outcomes. This marks a shift from the rigid warnings that dominated medical guidelines a decade ago.

What the Data Shows

Researchers examined prostate-specific antigen (PSA) levels and prostate volume in men on TRT. In most patients, these markers remained stable or showed only minor, clinically insignificant changes. For men with BPH, symptoms like urinary frequency or weak stream did not consistently worsen with therapy.

Even in men with a history of treated prostate cancer, some studies found no increased risk of recurrence among those on TRT, provided they had low-risk disease and were closely followed. The key takeaway: blanket bans on TRT for men with prostate issues may be outdated.

Risks Remain for Certain Groups

The evidence is not all green lights. The review noted that men with untreated, advanced, or high-risk prostate cancer should still avoid TRT. Similarly, those with severe lower urinary tract symptoms from BPH may not be ideal candidates without careful evaluation.

Experts stress that individual risk assessment is critical. A man's baseline PSA, digital rectal exam findings, and overall health profile matter more than a general diagnosis of prostate enlargement or early-stage cancer.

Clinical Recommendations Evolve

Endocrinologists and urologists are increasingly adopting a more nuanced approach. The review supports the idea that TRT can be considered in hypogonadal men—those with clinically low testosterone—even if they have a history of BPH or low-risk prostate cancer, as long as they are monitored every three to six months.

This means regular PSA checks, symptom questionnaires, and physical exams are non-negotiable. Patients should also be informed about the signs of prostate trouble, such as blood in urine or new-onset erectile dysfunction, and report them immediately.

What to Watch For Next

Larger, longer-term trials are still needed to confirm these findings across diverse populations. For now, the conversation between a patient and his doctor should focus on individual risk versus benefit—not fear. As the evidence evolves, guidelines may soon reflect a more flexible stance on TRT in men with prostate concerns.